These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Bjornsti MA, Benedetti P, Viglianti GA, Wang JC. Cancer Res; 1989 Nov 15; 49(22):6318-23. PubMed ID: 2553253 [Abstract] [Full Text] [Related]
3. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Eng WK, Faucette L, Johnson RK, Sternglanz R. Mol Pharmacol; 1988 Dec 15; 34(6):755-60. PubMed ID: 2849043 [Abstract] [Full Text] [Related]
7. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Wang LF, Ting CY, Lo CK, Su JS, Mickley LA, Fojo AT, Whang-Peng J, Hwang J. Cancer Res; 1997 Apr 15; 57(8):1516-22. PubMed ID: 9108454 [Abstract] [Full Text] [Related]
8. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Wasserman RA, Wang JC. Cancer Res; 1994 Apr 01; 54(7):1795-800. PubMed ID: 8137294 [Abstract] [Full Text] [Related]
9. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Cancer Res; 1995 Mar 15; 55(6):1339-46. PubMed ID: 7882333 [Abstract] [Full Text] [Related]
10. Mechanisms of camptothecin resistance by human topoisomerase I mutations. Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L, Redinbo MR. J Mol Biol; 2004 Jun 11; 339(4):773-84. PubMed ID: 15165849 [Abstract] [Full Text] [Related]
15. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G, Pommier Y. Cancer Res; 2001 Jan 15; 61(2):504-8. PubMed ID: 11212241 [Abstract] [Full Text] [Related]
16. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Chang JY, Liu JF, Juang SH, Liu TW, Chen LT. Cancer Res; 2002 Jul 01; 62(13):3716-21. PubMed ID: 12097280 [Abstract] [Full Text] [Related]
17. Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins. Alessandri M, Beretta GL, Ferretti E, Mancia A, Khobta A, Capranico G. J Mol Biol; 2004 Mar 19; 337(2):295-305. PubMed ID: 15003448 [Abstract] [Full Text] [Related]
18. A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons. Knab AM, Fertala J, Bjornsti MA. J Biol Chem; 1995 Mar 17; 270(11):6141-8. PubMed ID: 7890748 [Abstract] [Full Text] [Related]
19. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Antony S, Jayaraman M, Laco G, Kohlhagen G, Kohn KW, Cushman M, Pommier Y. Cancer Res; 2003 Nov 01; 63(21):7428-35. PubMed ID: 14612542 [Abstract] [Full Text] [Related]
20. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. Knab AM, Fertala J, Bjornsti MA. J Biol Chem; 1993 Oct 25; 268(30):22322-30. PubMed ID: 8226741 [Abstract] [Full Text] [Related] Page: [Next] [New Search]